The invention relates to the pharmaceutical and medical industries, in particular, to PEG-
interferon derivatives and the discovery of new, highly functional, highly stable cross-linkers of the resulting
protein to
polyethylene glycol, which have a measured alpha-reactivity of the resulting
protein, with reduced
immunogenicity, with prolonged biological effects and a factor relating to the amount of
drug available to the body over a period of time, which has been improved by the general formula (I) where: n - an integer value from 227 to 10000, so that the molecular weight of PEG- is about 10 000 -40 000 Da; m - an integer > 4; IFN - a natural or cellular polypeptide in which there is a combination of transcription units with a measured IFN-alpha-reactivity.The invention also relates to a medicament comprising the disclosed
linker of formula (I), a pharmaceutical composition comprising the PEG-IFN
linker and a pharmaceutically acceptable
excipient suitable for the treatment of viral infections and
cancer, as well as diseases associated with primary and secondary immune responses. The invention relates to the use of the
linker of formula (I) in a
medical product, which is characterized by its antiviral, antiproliferative and immunomodulatory properties, to a method for the prevention and / or treatment of diseases associated with primary or secondary immune responses, comprising administering an ayurvedic effective amount of the linker of formula (I), and to a container containing said pharmaceutical composition.